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Ligustrazine potently inhibits hypoxic pulmonary vasoconstriction. This effect can be mimicked by the sulphonylurea tolbutamide, a blocker of 
ATP-sensitive K’ channels. Here we demonstrate that ligustrazine is a specific blocker of ATP-sensitive K+ channels in mouse pancreatic fi cells. 
This suggests that ligustrazine may act in the pulmonary circulation by blocking ATP-sensitive K+ channels. 
Ligustrazine; ATFsensitive potassium channel; Potassium current; Pancreatic p cell 
1. INTRODUCTION 
Ligustrazine is a purified and chemicaliy identified 
component of a Chinese herbal remedy, which is a po- 
tent blocker of hypoxic pulmonary vasoconstriction in 
the rat [ 11. Recent studies have shown that tolbut~ide, 
a selective blocker of ATP-sensitive K ’ channels (K- 
ATP channels) [Z], also blocks hypoxic pulmona~ 
vasoconstriction ]3] and that high concentrations of 
d&oxide (an opener of these channels in pancreatic P 
cells [2]) constricts the vessels of the pulmonary circula- 
tion [3]. These findings suggest hat K-ATP channels 
are involved in the responses of the p~monary 
vasculature to hypoxia and it is therefore possible that 
ligustrazine also exerts its effect on the pulmonary 
vasculature by blocking them. Such a suggestion would 
be supported by demonstrating that ligustrazine selec- 
tively blocks the K-ATP channels of a preparation in 
which they are well described. We have therefore 
studied the effects of ligustrazine on the K-ATP (and 
other) K+ channels of pancreatic fi cells from the 
mouse, 
2. MATERIALS AND METHODS 
Single pancreatic @ cells of NMRI mice were isolated and maintain- 
ed in primary tissue culture for up to 3 days as previously described 
[2,4] and their K+ currents were recorded using the whole-cell con- 
figuration of the patch clamp technique 151. The extracellular medium 
contained (in mM); NaCl, 135; KCI, 5; MgS04, 1.2; CaCla, 2.5; 
NaOH-HEPES, 5; 21-24”C, pH 7.4. To study K-ATP currents, the 
pipette solution contained (in mM); KCI, 107; CaCl2, 1; MgS04, 2; 
NaCl, 10; K-EGTA, 11; KOH-HEPES, 11; ATP, 0.3; pH 7.2. The 
small amount of ATP was included to prevent K-ATP channel run- 
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down [2]. When studying voltage-activated currents the ATP- 
sensitive component was blocked by increasing the intracellular ATP 
level to 5 mM, and adding 0.2 mM tolbutamide (Rastinon, Hoechst) 
to the extracellular medium. Currents were recorded using an Ax- 
opatch (Axon Instruments) and analysed as previously described [6]. 
Diazoxide (Eudemine) was obtained from Allen and Hanbury, Green- 
ford, U.K. Ligustrazine was dissolved in distilled water. 
3. RESULTS 
We measured K-ATP currents as the response to 10 
mV depolarizing voltage steps (200 ms duration, 0.5 
Hz) from a holding potential of -70 mV: an experimen- 
tal protocol which measures only current through K- 
ATP channels [2,7]. Characteristic features of this cur- 
rent were: (i) On first obtaining the whole-cell con- 
figuration the currents were small but then increased in 
amplitude (run-up) as intracellular ATP was dialysed 
from the cell, reflecting the relief of ATP inhibition of 
K-ATP channels (fig,lA). A reduction of the negative 
holding current accompanied this run-up. (ii) The ap- 
plication to the bath of 0.2 mM tolbutamide, a specific 
and potent blocker of K-ATP channels [2,7], resulted in 
rapid, reversible inhibition of this conductance and an 
increase in the holding current (fig.lB). The rate at 
which tolbutamide inhibited K-ATP currents reflected 
the rate of exchange of the bath solutions. 
Fig.2 shows that 0.74 mM ligustrazine inhibited K- 
ATP currents (by 34.2 -t 1.3070, mean f S.E.M., n = 
8 cells). The response to ligustrazine was much slower 
than that to tolbutamide, but similar to that of the more 
potent sulphonylurea glibenclamide [7]. Doubling the 
dose of ligustrazine to 1.48 mM did not significantly 
change the percentage inhibition (32.4 + 1.3%; n = 6; 
P>O.d, unpaired Student’s t-test) suggesting that the 
lower dose is maximal. However, 74 PM ligustr~ine 
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Fig.1. (A) ‘Run-up’ of K-ATP conductance, 20 s after achieving 
whole-cell configuration. (B) Inhibition of K-ATP conductance by 
bath application of 0.2 mM tolbutamide (horizontal bar). Insert 
shows structure of tolbutamide. 
was without detectable ffect (not shown). As shown in 
fig.2 recovery of the K-ATP conductance following 
removal of 0.74 mM ligustrazine from the bath was ex- 
tremely variable. This variability appeared to be in- 
dependent of the duration of its application. 
D&oxide is a potent activator of K-ATP channels 
which reverses the blocking effect of tolbutamide [2,7]. 
Fig.3 demonstrates that bath application of 0.4 mM 
diazoxide rapidly reversed the effect of ligustrazine, 
evoking a current which was in many cases greater than 
the control level. This effect was observed both during 
the continued presence of ligustrazine (fig.3A) and also 
after its removal when the recovery of K-ATP currents 
was incomplete (fig.3B). This latter finding suggests 
that the failure of K-ATP currents to recover after 
ligustrazine was not due to their running-down, as 
d&oxide does not reactivate channels subject to run- 
down [7]. 
Effect of ligustrazine on voltage activated K-currents 
Voltage activated K+ currents elicited by stepping to 
various depolarized test potentials from a holding 
potential of -80 mV were similar to those described in 
the literature [4]. These outward currents arise when 
delayed rectifier (IK-V) and calcium activated (IK-Ca) 
potassium channels are activated and they are followed 
by a slow decay to a new steady state which consists ex- 
clusively of IK-V (fig.4A, control; [9]). Fig.4A shows 
that the addition of ligustrazine to the bath had no ef- 







Fig.2. Effects of ligustrazine on K-ATP conductance (applied as 
shown by horizontal bar). (A) Record from one cell showing rever- 
sibility of inhibition, contrasting with (B) showing little or no 
recovery, recorded in another cell. Insert shows structure of 
ligustrazine. 
end of the pulse. Under these experimental conditions 
the calcium current runs down [8], reducing the con- 
tribution of IK-Ca and making it impossible to measure 
its modulation by ligustrazine accurately. However, in 
a few cases ligustrazine was added before the IK-Ca 
component had run down appreciably, and in such ex- 
periments ligustrazine had no detectable ffect on the 
peak current amplitude (e.g. fig.4A, upper traces). At 
0.4mM diazoxide 
A 1.48mM ligustrazine 
50pA 
B 
0.74mM ligustrazine 0.4mM diazoxide 
50pA 
Fig.3. Activation of K-ATP conductance by 0.4 mM diazoxide, ap- 
plied (A) in the presence of ligustrazine and (B) following removal of 
ligustrazine in a cell that did not show recovery before application of 
diazoxide (A and B different cells). 
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Fig.4. (A) Effects of 0.74 mM ligustrazine and 20 mM tetraethylam- 
monium (TEA) on whole-cell K+ current amplitudes. with K-ATP 
channels blocked by 5 mM ATP in the pipette and 0.2 mM 
tolbutamide in the bath. Upper traces, representative examples of cur- 
rents activated by 500 ms depolarizing steps to + 20 mV. Lower trace, 
time series of steady state current amplitudes (IK-V), recorded before 
and during application of 0.74 mM ligustrazine and 20 mM TEA, in- 
dicated by horizontal bars. (B) Current-voltage relationship of IK-V 
in another cell before and during application of 0.74 mM ligustrazine. 
the end of 500 ms pulse, IK-Ca is always completely in- 
activated because its time course closely mirrors that of 
the transient Ca2 + current [9] and this allows a measure 
of IK-V alone. Ligustrazine (0.74 mM) was virtually 
without effect on IK-V, unlike 20 mM TEA which caus- 
ed an almost complete block of the outward current 
(fig.4A), an observation consistent with its known abili- 
ty to block IK-V both rapidly and reversibly at this dose 
[4]. Fig.4B demonstrates that ligustrazine was virtually 
without effect over the complete range of activating test 
potentials studied. Similar results were observed in 7 
other cells. 
4. DISCUSSION 
We have demonstrated that ligustrazine is a novel 
blocker of K-ATP channels in mouse pancreatic &cells 
which has almost no effect on IK-Ca or IK-V. Its action 
therefore resembles that of the sulphonylurea 
tolbutamide in that it appears to be specific for K-ATP 
channels and its effects can be reversed by diazoxide. 
However, ligustrazine differs from tolbutamide in the 
following respects: (i) its maximum effect is reached 
more slowly; (ii) it is less potent, maximally suppressing 
conductance by only 30-35% and (iii) recovery from its 
block is often incomplete. Such differences are perhaps 
not surprising in view of their dissimilar structures (figs. 
1 and 2). The slow rate of onset of ligustrazine block, 
and in some cases the duration of its action (e.g. fig. 2B) 
are reminiscent of the block of K-ATP channels by 
glibenclamide. However, unlike glibenclamide [7], the 
effects of ligustrazine are reversed by diazoxide (fig. 3). 
Our findings are consistent with the idea that 
ligustrazine blocks hypoxic pulmonary vasoconstriction 
by modulating K-ATP channels in the pulmonary 
vasculature (see section 1). We know of no reports that 
describe the effects of ligustrazine on blood glucose or 
insulin levels but suppose that this would be unlikely 
because it is so much less potent than tolbutamide in B 
cells. However, the converse is true in the pulmonary 
vasculature where ligustrazine is a far more potent 
blocker of hypoxic pulmonary vasoconstriction than 
tolbutamide [ 1,3]. 
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